JUPITER Subanalysis: Reduction of LDL Determines Clinical Impact of Rosuvastatin Therapy

Original Title: Cholesterol treatment targets and clinical outcomes: a JUPITER trial update.
Presenter: Paul Ridker.

The lower the LDL cholesterol levels, the less adverse cardiovascular events in men and women initially healthy, according to an analysis of the JUPITER trial. Findings could help inform about the optimal LDL goals in primary prevention.

To explore the link between percent reduction of LDL and outcomes, Ridker and colleagues analyzed data from the JUPITER trial that included 17,802 patients initially healthy randomized to 20 mg of rosuvastatin (Crestor; AstraZeneca) or placebo, followed up through five years.

Median percent reduction in LDL cholesterol with rosuvastatin was 50%, despite the ample variability across the study population. A small proportion of patients saw no LDL reduction, half saw at least a 50% drop, and the rest, a smaller reduction.

The rate of first-ever MI, stroke, hospitalization for unstable angina requiring coronary intervention, or cardiovascular death (primary endpoint) per 1,000 person-years was 11.2 with placebo, 9.2 for those with no reduction in LDL cholesterol (RR 0.86), 6.7 for those with a less than 50% reduction (RR 0.61), and 4.8 for those with at least a 50% reduction (RR 0.41; P <0.00001 for trend).

The findings could be relevant now that PCSK9 inhibitors are emerging as a new class of lipid-lowering drugs. Patients with large reductions in LDL cholesterol on statins would see, in theory, less benefits with the new agents and those with smaller or no reductions would possibly have the most benefits.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...